Alnylam Pharmaceuticals, Inc. (0HD2.L) LSE

366.52

-2.39(-0.65%)

Updated at January 14 02:50PM

Currency In USD

Valuation

Market Cap30.45B
Enterprise Value32.27B
P/E Ratio1,116.27
PEG Ratio9.92
Price/Sales Ratio15.23
Price/Book Ratio207.92
Enterprise/Revenue15.63
Enterprise/EBITDA268.89

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin0.01
Operating Margin0.08

Management Effectiveness

Return On Assets0.01
Return On Equity0.26

Income Statement

Revenue2.25B
Revenue/Share24.42
Gross Profit1.92B
EBITDA-178.85M
Net Income-278.16M
Diluted EPS-2.18

Balance Sheet

Total Cash2.72B
Total Cash/Share20.73
Total Debt2.77B
Total Debt/Equity11.86
Current Ratio2.54
Book Value Per Share1.78

Price History

52-Week Change48.75
52-Week High375.66
52-Week Low143.66
Moving Average 50 Days170.73
Moving Average 200 Days180.79

Statistics

Average Volume1,441
Shares Outstanding132.12M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A